Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing Lucid-MS, a patented first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis (MS), according to an editorial published by AINewsWire. Unlike existing MS therapies that primarily target the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective compound intended to prevent myelin degradation. The company recently filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration and is preparing for a Phase 2 clinical trial following successful completion of Phase 1 safety studies and key toxicology programs.
The editorial highlighted more than a decade of preclinical research supporting Lucid-MS, including studies showing preservation of myelin integrity, reduced degradation and improved functional recovery in animal models. Quantum BioPharma is also collaborating with Massachusetts General Hospital on validation of a novel PET imaging technique designed to directly measure myelin integrity in MS patients, a tool that could help evaluate the effectiveness of remyelinating therapies. The report also noted recent clinical and regulatory developments from Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and Bristol Myers Squibb Company (NYSE: BMY), underscoring continued innovation across autoimmune, immune-mediated and chronic inflammatory disease treatment markets.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
The company also invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement includes royalty payments of 7% of sales from UNBUZZD(TM) until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The advancement of Lucid-MS into Phase 2 trials represents a potential shift in MS treatment, offering a neuroprotective approach rather than immune modulation. If successful, Lucid-MS could address an unmet need for therapies that directly prevent myelin damage and promote repair, potentially slowing or halting disease progression. The collaboration with Massachusetts General Hospital on PET imaging could also provide a non-invasive method to monitor myelin integrity, aiding in clinical development and future patient management.
